| c-abl Oncogene and chromosome 22 bcr juxtaposition in chronic myelogenous leukemia. | leukemia, |
| Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. | leukemia, |
| Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture. | leukemia, |
| An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. | leukemia, |
| The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. | leukemia, |
| Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. | leukemia, |
| Frequent jumping translocations of chromosomal segments involving the ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemias. | leukemia, |
| Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. | leukemia, |
| Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. | None |
| Regulation of human c-Abl tyrosine kinase activity in Xenopus oocytes and acceleration of progesterone-induced G2/M transition by oncogenic forms. | None |
| Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. | None |
| A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. | None |
| Bcr: a negative regulator of the Bcr-Abl oncoprotein. | None |
| Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). | None |
| The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. | None |
| In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. | None |
| The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. | None |
| Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. | None |
| A novel four zinc-finger protein targeted against p190(BcrAbl) fusion oncogene cDNA: utilisation of zinc-finger recognition codes. | None |
| Transformation to acute leukaemia in an MDS patient harbouring bcr-abl and bcl 2-IgH rearrangements, without expression of either activated oncogene. | None |